HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: dc06-1549v1 30/7/1709    most recent Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Laferrère, B. Articles by Olivan, B. Search for Related Content PubMed PubMed Citation Articles by Laferrère, B. Articles by Olivan, B. Social Bookmarking                What's this?

Incretin Levels and Effect Are Markedly Enhanced 1 Month After Roux-en-Y Gastric Bypass Surgery in Obese Patients With Type 2 Diabetes

¹ Obesity Research Center, St. Luke's/Roosevelt Hospital Center, Columbia University College of Physicians and Surgeons, New York, New York
² Bariatric Division, St. Luke's/Roosevelt Hospital Center, Columbia University College of Physicians and Surgeons, New York, New York

Address correspondence and reprint requests to Blandine Laferrère, MD, Obesity Research Center, St. Luke's/Roosevelt Hospital Center, Columbia University College of Physicians and Surgeons, 1111 Amsterdam Ave., New York, NY 10025. E-mail: bbl14{at}columbia.edu

OBJECTIVE— Limited data on patients undergoing Roux-en-Y gastric bypass surgery (RY-GBP) suggest that an improvement in insulin secretion after surgery occurs rapidly and thus may not be wholly accounted for by weight loss. We hypothesized that in obese patients with type 2 diabetes the impaired levels and effect of incretins changed as a consequence of RY-GBP.

RESEARCH DESIGN AND METHODS— Incretin (gastric inhibitory peptide [GIP] and glucagon-like peptide-1 [GLP-1]) levels and their effect on insulin secretion were measured before and 1 month after RY-GBP in eight obese women with type 2 diabetes and in seven obese nondiabetic control subjects. The incretin effect was measured as the difference in insulin secretion (area under the curve [AUC]) in response to an oral glucose tolerance test (OGTT) and to an isoglycemic intravenous glucose test.

RESULTS— Fasting and stimulated levels of GLP-1 and GIP were not different between control subjects and patients with type 2 diabetes before the surgery. One month after RY-GBP, body weight decreased by 9.2 ± 7.0 kg, oral glucose-stimulated GLP-1 (AUC) and GIP peak levels increased significantly by 24.3 ± 7.9 pmol · l^–1 · min^–1 (P < 0.0001) and 131 ± 85 pg/ml (P = 0.007), respectively. The blunted incretin effect markedly increased from 7.6 ± 28.7 to 42.5 ± 11.3 (P = 0.005) after RY-GBP, at which it time was not different from that for the control subjects (53.6 ± 23.5%, P = 0.284).

CONCLUSIONS— These data suggest that early after RY-GBP, greater GLP-1 and GIP release could be a potential mediator of improved insulin secretion.

Abbreviations: AUC, area under the curve • BPD, biliopancreatic diversion • DPPIV, dipeptidyl-peptidase IV • GIP, gastric inhibitory peptide • GLP-1, glucagon-like peptide-1 • IsoG IVGT, isoglycemic intravenous glucose test • IV, intravenous • JIB, jejunoileal bypass • OGTT, oral glucose tolerance test • RY-GBP, Roux-en-Y gastric bypass surgery

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				E. Muscelli, A. Mari, A. Casolaro, S. Camastra, G. Seghieri, A. Gastaldelli, J. J. Holst, and E. Ferrannini Separate Impact of Obesity and Glucose Tolerance on the Incretin Effect in Normal Subjects and Type 2 Diabetic Patients Diabetes, May 1, 2008; 57(5): 1340 - 1348. [Abstract] [Full Text] [PDF]

				P. A. Velasquez-Mieyer, P. A. Cowan, S. Perez-Faustinelli, R. Nieto-Martinez, C. Villegas-Barreto, E. A. Tolley, R. H. Lustig, and B. S. Alpert Racial Disparity in Glucagon-Like Peptide 1 and Inflammation Markers Among Severely Obese Adolescents Diabetes Care, April 1, 2008; 31(4): 770 - 775. [Abstract] [Full Text] [PDF]

				M. J. Fowler Diabetes Treatment, Part 3: Insulin and Incretins Clin. Diabetes, January 1, 2008; 26(1): 35 - 39. [Full Text] [PDF]

				A. B. Goldfine, E. C. Mun, E. Devine, R. Bernier, M. Baz-Hecht, D. B. Jones, B. E. Schneider, J. J. Holst, and M. E. Patti Patients with Neuroglycopenia after Gastric Bypass Surgery Have Exaggerated Incretin and Insulin Secretory Responses to a Mixed Meal J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4678 - 4685. [Abstract] [Full Text] [PDF]

				H.-J. Jang, Z. Kokrashvili, M. J. Theodorakis, O. D. Carlson, B.-J. Kim, J. Zhou, H. H. Kim, X. Xu, S. L. Chan, M. Juhaszova, et al. Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1 PNAS, September 18, 2007; 104(38): 15069 - 15074. [Abstract] [Full Text] [PDF]